Skip to main content
CDK4/6 Inhibitors
A Payer’s Perspective on CDK4/6 Inhibitors
Kenneth L. Schaecher, MD, FACP, CPC
Read More
CDK4/6 Inhibitors
A Nurse Navigator’s Perspective on CDK4/6 Inhibitors
Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN
Read More
Original Research
Impact of Pharmacist-Driven Educational Intervention on Documentation of Bowel Function Assessment in Patients with Cancer Who Are Using Opioids
Kimberly N. Flynn, PharmD, BCPS, Celestine Gochett, PhD, AOCNS
Read More
Original Research
Microbial Growth of Single-Dose Antineoplastic Drug Vials at 28 Days
Elizabeth R. Pritchard, PharmD, BCOP, J. Aubrey Waddell, PharmD, FAPhA, BCOP, Brad J. Crane, PharmD, BCPS, Amy M. Porter, PharmD, Susan Roberts, PharmD, Danielle M. Yates, PharmD, Angelia M. Thomas, MT (ASCP)
Read More
FDA Updates
The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers
Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, RPh, PhD
Read More
Case Reports
Aplastic Anemia in a Patient with Anaplastic Oligodendroglioma Postradiation and Concurrent Temozolomide Therapy: Case Report and Review of the Literature
Kirollos S. Hanna, PharmD, BCPS, BCOP, Robert Mancini, PharmD, BCOP, FHOPA, Matthew Burtelow, MD, PhD, Benjamin Bridges, MD
Read More
Symptom Management Overview
Prevention of Thromboembolism in Patients with Multiple Myeloma
Nicole Gerardo, PharmD
Read More
FDA Updates
Recent Cancer Drugs Approved by the FDA
Read More
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Read More
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL
Read More
Page 163 of 200
Results 1621 - 1630 of 1993